PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with
                    <i>EGFR</i>
                    and
                    <i>ERBB2</i>
                    Mutations that Are Resistant to Gefitinib

A. Engelman, Jeffrey; Zejnullahu, Kreshnik; Gale, Christopher-Michael; Lifshits, Eugene; J. Gonzales, Andrea; Shimamura, Takeshi; Zhao, Feng; W. Vincent, Patrick; N. Naumov, George; E. Bradner, James; W. Althaus, Irene; Gandhi, Leena; I. Shapiro, Geoffrey; M. Nelson, James; V. Heymach, John; Meyerson, Matthew; Wong, Kwok-Kin; A. Jänne, Pasi

doi:10.1158/0008-5472.can-07-1885

Public

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Shared by NobleBlocks on Dec 15, 2007 • 12:00 AM UTC

Authors:

Jeffrey A. Engelman

Kreshnik Zejnullahu

Christopher-Michael Gale

Abstract

Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non–small cell lung cancers. In particular, cancers with specific EGFR-activating mutations seem to be the most sensitive to these agents. However, despite the...

Discussions